The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice #
Open accessAbstract
Hepatic steatosis is a hallmark of nonalcoholic fatty liver disease (NAFLD) and a key component of obesity-associated metabolic dysfunctions featuring dyslipidemia, insulin resistance, and loss of glycemic control. It has yet to be completely understood how much dysregulated de novo lipogenesis contributes to the pathogenic development of hepatic steatosis and insulin resistance. ATP-citrate lyase (ACL) is a lipogenic enzyme that catalyzes the critical reaction linking cellular glucose catabolism and lipogenesis, converting cytosolic citrate to acetyl-coenzyme A (CoA). Acetyl-CoA is further converted to malonyl-CoA, the essential precursor for fatty acid biosynthesis. We investigated whether dysregulation of hepatic ACL is metabolically connected to hepatic steatosis, insulin resistance, and hyperglycemia. We found that in leptin receptor–deficient db/db mice, the expression of ACL was selectively elevated in the liver but not in the white adipose tissue. Liver-specific ACL abrogation via adenovirus-mediated RNA interference prominently reduced the hepatic contents of both acetyl-CoA and malonyl-CoA, markedly inhibited hepatic de novo lipogenesis, and protected against hepatic steatosis in db/db mice. Surprisingly, liver-specific ACL abrogation markedly inhibited the expression of peroxisome proliferator-activated receptor-gamma and the entire lipogenic program in the liver. Moreover, hepatic ACL deficiency resulted in significantly down-regulated expression of gluconeogenic genes in the liver as well as enhanced insulin sensitivity in the muscle, leading to substantially improved systemic glucose metabolism. Conclusion: These findings establish a crucial role of hepatic ACL in lipid and glucose metabolism; therefore, hepatic ACL may serve as a potential target to treat NAFLD and type 2 diabetes. (Hepatology 2009.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leptin and the regulation of body weight in mammals
Friedman, J. M., & Halaas, J. L. (1998) · Nature · doi:10.1038/27376 · Cited by 5,405
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1
Yoon, J. C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C. R., Granner, D. K., et al. (2001) · Nature · doi:10.1038/35093050 · Cited by 1,821
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
The Mitochondrial Carnitine Palmitoyltransferase System — From Concept to Molecular Analysis
McGarry, J. D., & Brown, N. F. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00001.x · Cited by 1,616
Mechanism of free fatty acid-induced insulin resistance in humans.
Roden, M., Price, T. B., Perseghin, G., Petersen, K. F., Rothman, D. L., Cline, G. W., & Shulman, G. I. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118742 · Cited by 1,539
Mechanisms of leptin action and leptin resistance.
Myers, M. G., Cowley, M. A., & Münzberg, H. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100707 · Cited by 1,074
Liver X receptors as integrators of metabolic and inflammatory signaling
Zelcer, N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27883 · Cited by 978
A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis.
McGarry, J. D., Mannaerts, G. P., & Foster, D. W. (1977) · Journal of Clinical Investigation · doi:10.1172/jci108764 · Cited by 736
Research works printed but not linked: 33
- NeuschwanderTetri, 2003, Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference., HEPATOLOGY, 37, 1202, 10.1053/jhep.2003.50193 · DOI · Paper page
- Adams, 2007, Nonalcoholic fatty liver disease., Ann Epidemiol, 17, 863, 10.1016/j.annepidem.2007.05.013 · DOI · Paper page
- Farrell, 2006, Nonalcoholic fatty liver disease: from steatosis to cirrhosis., HEPATOLOGY, 43, S99, 10.1002/hep.20973 · DOI · Paper page
- Brunt, 2007, Pathology of fatty liver disease., Mod Pathol, S40, 10.1038/modpathol.3800680 · DOI · Paper page
- Marchesini, 2003, Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome., HEPATOLOGY, 37, 917, 10.1053/jhep.2003.50161 · DOI · Paper page
- Wieckowska, 2007, Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future., HEPATOLOGY, 46, 582, 10.1002/hep.21768 · DOI · Paper page
- Watanabe, 2008, Liver diseases and metabolic syndrome., J Gastroenterol, 43, 509, 10.1007/s00535-008-2193-6 · DOI
- Rector, 2008, Nonalcoholic fatty liver disease and the metabolic syndrome: an update., World J Gastroenterol, 14, 185, 10.3748/wjg.14.185 · DOI · Paper page
- Postic, 2008, Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice., J Clin Invest, 118, 829, 10.1172/JCI34275 · DOI · Paper page
- Wakil, 1983, Fatty acid synthesis and its regulation., Ann Rev Biochem, 52, 537, 10.1146/annurev.bi.52.070183.002541 · DOI · Paper page
- Srere, 1959, The Citrate Cleavage Enzyme. I. Distribution and purification., J Biol Chem, 234, 2544, 10.1016/S0021-9258(18)69735-2 · DOI · Paper page
- Yu, 2003, Adipocytespecific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferatoractivated receptor gamma 1 (PPARgamma 1) overexpression., J Biol Chem, 278, 498, 10.1074/jbc.M210062200 · DOI · Paper page
- Herzig, 2003, CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR., Nature, 426, 190, 10.1038/nature02110 · DOI · Paper page
- Schultz, 2000, Role of LXRs in control of lipogenesis., Genes Dev, 14, 2831, 10.1101/gad.850400 · DOI · Paper page
- Shimano, 1999, Sterol regulatory elementbinding protein1 as a key transcription factor for nutritional induction of lipogenic enzyme genes., J Biol Chem, 274, 35832, 10.1074/jbc.274.50.35832 · DOI · Paper page
- Uyeda, 2006, Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis., Cell Metab, 4, 107, 10.1016/j.cmet.2006.06.008 · DOI · Paper page
- Denechaud, 2008, ChREBP, but not LXRs, is required for the induction of glucoseregulated genes in mouse liver., J Clin Invest, 118, 956
- Lewis, 2002, Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes., Endocr Rev, 23, 201, 10.1210/edrv.23.2.0461 · DOI · Paper page
- Mao, 2006, Liverspecific deletion of acetylCoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis., Proc Natl Acad Sci U S A, 103, 8552, 10.1073/pnas.0603115103 · DOI · Paper page
- Chakravarthy, 2005, New hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis., Cell Metab, 1, 309, 10.1016/j.cmet.2005.04.002 · DOI · Paper page
- Miyazaki, 2007, Hepatic stearoylCoA desaturase1 deficiency protects mice from carbohydrateinduced adiposity and hepatic steatosis., Cell Metab, 6, 484, 10.1016/j.cmet.2007.10.014 · DOI · Paper page
- Matsuzaka, 2007, Crucial role of a longchain fatty acid elongase, Elovl6, in obesityinduced insulin resistance., Nat Med, 13, 1193, 10.1038/nm1662 · DOI · Paper page
- Beigneux, 2004, ATPcitrate lyase deficiency in the mouse., J Biol Chem, 279, 9557, 10.1074/jbc.M310512200 · DOI
- Lin, 2005, Hyperlipidemic effects of dietary saturated fats mediated through PGC1 coactivation of SREBP., Cell, 120, 261, 10.1016/j.cell.2004.11.043 · DOI · Paper page
- Repa, 2000, Regulation of mouse sterol regulatory elementbinding protein1c gene (SREBP1c) by oxysterol receptors, LXRalpha and LXRbeta., Genes Dev, 14, 2819, 10.1101/gad.844900 · DOI · Paper page
- Lefebvre, 2006, Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis., J Clin Invest, 116, 571, 10.1172/JCI27989 · DOI · Paper page
- Mu, 1999, Quantitative trait loci analysis for the differences in susceptibility to atherosclerosis and diabetes between inbred mouse strains C57BL6J and C57BLKSJ., J Lipid Res, 40, 1328, 10.1016/S0022-2275(20)33495-7 · DOI
- Matsusue, 2003, Liverspecific disruption of PPARgamma in leptindeficient mice improves fatty liver but aggravates diabetic phenotypes., J Clin Invest, 111, 737, 10.1172/JCI200317223 · DOI · Paper page
- Pearce, 1998, The role of ATP citratelyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB204990, a lactone prodrug of the potent ATP citratelyase inhibitor SB201076., Biochem J, 334, 113, 10.1042/bj3340113 · DOI
- Dentin, 2006, Liverspecific inhibition of ChREBP improves hepatic steatosis and insulin resistance in obob mice., Diabetes, 55, 2159, 10.2337/db06-0200 · DOI · Paper page
- Leone, 1999, A critical role for the peroxisome proliferatoractivated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalphanull mouse as a model of fatty acid oxidation disorders., Proc Natl Acad Sci U S A, 96, 7473, 10.1073/pnas.96.13.7473 · DOI · Paper page
- Kersten, 1999, Peroxisome proliferatoractivated receptor alpha mediates the adaptive response to fasting., J Clin Invest, 103, 1489, 10.1172/JCI6223 · DOI · Paper page
- Memon, 2000, Upregulation of peroxisome proliferatoractivated receptors (PPARalpha) and PPARgamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPARgammaresponsive adipose tissuespecific genes in the liver of obese diabetic mice., Endocrinology, 141, 4021, 10.1210/endo.141.11.7771 · DOI · Paper page
Cited by
Metabolic Syndrome: Updates on Pathophysiology and Management in 2021
Fahed, G., Aoun, L., Bou Zerdan, M., Allam, S., Bou Zerdan, M., Bouferraa, Y., & Assi, H. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020786 · Cited by 1,441
Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease
Softic, S., Cohen, D. E., & Kahn, C. R. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4054-0 · Cited by 709
Metabolic-associated fatty liver disease and lipoprotein metabolism
Heeren, J., & Scheja, L. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101238 · Cited by 646
Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate
Zhao, S., Jang, C., Liu, J., Uehara, K., Gilbert, M., Izzo, L., Zeng, X., Trefely, S., Fernandez, S., Carrer, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2101-7 · Cited by 553
Ahrens, M., Ammerpohl, O., von Schönfels, W., Kolarova, J., Bens, S., Itzel, T., Teufel, A., Herrmann, A., Brosch, M., Hinrichsen, H., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.07.004 · Cited by 546
Metadata
- Authors
- Wang, Q., Jiang, L., Wang, J., Li, S., Yu, Y., You, J., Zeng, R., Gao, X., Rui, L., Li, W., & Liu, Y.
- Venue
- Hepatology
- Published
- 2009-04
- Volume
- 49
- Issue
- 4
- Pages
- 1166-1175
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2028874440
- Cited by
- 213
- References
- 13
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 2344 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice #. https://app.cochat.ai/papers/10.1002/hep.22774
- The paper
- Wang, Q., Jiang, L., Wang, J., Li, S., Yu, Y., You, J., Zeng, R., Gao, X., Rui, L., Li, W., & Liu, Y. (2009). Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice #. Hepatology. https://doi.org/10.1002/hep.22774
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.